Danielle McClain
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1902597693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by Lilly USA, LLC at 25.9% of the total. 2025 is the largest year on record at $2,379, 4.8 times the $491 reported in 2023.
Across 221 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Dexcom, Inc.$465
- Novo Nordisk$361
- Corcept Therapeutics$285
- Abbott$274
- Radius Health, Inc.$255
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,816100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 62 | $1,250 |
| Dexcom, Inc. | 19 | $465 |
| Novo Nordisk | 15 | $361 |
| Corcept Therapeutics | 15 | $285 |
| Abbott | 13 | $274 |
| Radius Health, Inc. | 12 | $255 |
| Medtronic | 2 | $220 |
| Boehringer Ingelheim | 7 | $139 |
| Bayer | 9 | $136 |
| Amgen | 7 | $131 |
| Xeris Pharmaceuticals, Inc. | 7 | $121 |
| Verity Pharmaceuticals Inc. | 5 | $107 |
| Sequel Med Tech, LLC | 2 | $96 |
| Amneal Pharmaceuticals LLC | 5 | $94 |
| Mannkind Corporation | 5 | $88 |
| Sanofi-aventis U.S. LLC | 3 | $85 |
| Madrigal Pharmaceuticals | 2 | $65 |
| Cequr Corporation | 1 | $64 |
| Rhythm Pharmaceuticals, Inc. | 3 | $58 |
| Kyowa Kirin, Inc. | 2 | $54 |
| Recordati_rare_diseases_inc. | 3 | $53 |
| Amphastar Pharmaceuticals, Inc. | 3 | $50 |
| Chiesi USA, Inc. | 2 | $49 |
| Ascendis Pharma Endocrinology Inc | 2 | $46 |
| AstraZeneca | 2 | $41 |
| AbbVie | 2 | $29 |
| Tandem Diabetes Care, Inc. | 2 | $27 |
| Novartis | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$200
- Ozempic$102
How this compares
$4,816 in reported general payments places this provider in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $186,342 |
| MounjaroTirzepatide | 71 | $117,544 |
| JardianceEmpagliflozin | 40 | $49,922 |
| TrulicityDulaglutide | 29 | $47,163 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $19,847 |
| FarxigaDapagliflozin Propanediol | 12 | $15,263 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $11,270 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $11,049 |
| TradjentaLinagliptin | 11 | $8,875 |
| SynthroidLevothyroxine Sodium | 76 | $7,044 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $7,043 |
| Novolog FlexpenInsulin Aspart | 15 | $6,406 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $5,097 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 27 | $3,097 |
| Levothyroxine Sodium | 251 | $2,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $361 | $186,342118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,250 | $164,708100 claims |
| Boehringer IngelheimJardiance, Tradjenta | $139 | $58,79751 claims |
| AstraZenecaFarxiga | $41 | $15,26312 claims |
| AbbVieSynthroid | $29 | $7,04476 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $94 | $2,695251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.